SCIENTURE to commercially launch REZENOPY® opioid overdose emergency treatment

  SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC (“Scienture”), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. (“Kindeva”)), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.

https://www.globenewswire.com/news-release/2025/03/06/3038102/0/en/SCIENTURE-to-commercially-launch-REZENOPY-a-life-saving-opioid-overdose-emergency-treatment-through-a-collaboration-with-KINDEVA-DRUG-DELIVERY-L-P.html